Baskerville Capital plc
('Baskerville' or the 'Company')
Results of General Meeting
The Company is pleased to announce the results of the General Meeting ('GM') which was held earlier today. All the Resolutions were passed by way of a poll. As announced on 21 January 2021, the GM had been convened to approve Resolutions in connection with the Proposed Acquisition of Oberon Investments Limited, the proposed waiver of Rule 9 of the Takeover Code, and to authorise the directors to issue and allot new shares in connection with the Fundraising.
Admission of the Enlarged Share Capital to trading on the Access Segment of AQSE Growth Market is expected to take place, and dealings in the Company's Shares are expected to commence on the Access Segment of AQSE Growth Market, at 8.00 a.m. on 9 February 2021.
The Company is to be renamed "Oberon Investments Group plc". This will become effective upon the issue of a certificate of incorporation on change of name by the Registrar of Companies.
The Company has applied to the FCA for cancellation of admission of the Ordinary Shares to the Standard Segment of the Official List and to trading on the 's Main Market for listed securities to take effect at 8:00 a.m. on 9 February 2021.
Terms used and not defined in this announcement bear the meaning given to them in the Admission Document published on 21 January 2021.
Voting results will be made available to view shortly on the Company's website at www.baskcap.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
Baskerville Capital plc
|
|
Rodger Sargent, Chairman
|
via Walbrook PR
|
|
|
Rule 3 Adviser, AQSE Corporate Adviser and Broker
|
|
Novum Securities Limited
|
|
Richard Potts / Daphne Zhang / Lucy Bowden
|
020 7399 9400
|
|
|
Walbrook PR Ltd
|
Tel: 020 7933 8780 or baskerville@walbrookpr.com
|
|
|
This information is provided by RNS, the news service of the
. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
use the personal data you provide us, please see our
Privacy Policy.
END